Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma

National Cancer Institute (NCI)

Status and phase: Completed; Phase 2

Conditions: Recurrent Melanoma; Stage IV Melanoma

Treatments: Biological: gp100:209-217(210M) peptide vaccine; Biological: aldesleukin; Other: laboratory biomarker analysis

Study type: Interventional

Funder types: NIH

Identifiers

NCT00005949

NCI-2012-02337

CDR0000067886 (Registry Identifier)

U10CA031946 (U.S. NIH Grant/Contract)

CLB-509901

Details and patient eligibility

About

Phase II trial to study the effectiveness of vaccine therapy plus interleukin-2 in treating patients who have advanced melanoma. Vaccines made from a person's cancer cells may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Melanoma vaccine plus interleukin-2 may kill more cancer cells

Full description

PRIMARY OBJECTIVES:

I. Determine clinical response rates in patients with advanced melanoma treated with gp100:209-217(210M) melanoma vaccine and low-dose interleukin-2.

II. Assess response duration and progression-free intervals in these patients receiving this treatment.

OUTLINE:

Patients receive gp100:209-217(210M) emulsified in Montanide ISA-51 subcutaneously (SC) on day 1 and interleukin-2 SC on days 1-5 and 8-13. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. Patients with a complete response (CR) receive 3 additional courses after achieving CR.

Patients are followed every 9 weeks for 3 years or until disease recurrence.

PROJECTED ACCRUAL: A total of 25-50 patients will be accrued for this study within 3.5 years.

Enrollment: 50 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Histologically or cytologically confirmed cutaneous melanoma with clinical evidence of distant, metastatic, unresectable regional lymphatic, or extensive in-transit recurrent disease

• HLA-A2*0201 positive by genotyping

• Measurable disease as defined by the following:

  • At least 1 lesion accurately measured in at least 1 dimension

  • At least 20 mm by conventional techniques

  • At least 10 mm by spiral CT scan

  • Lesions considered intrinsically nonmeasurable include:

    • Bone lesions
    • Leptomeningeal disease
    • Ascites
    • Pleural/pericardial effusion
    • Inflammatory breast disease
    • Lymphangitis cutis/pulmonis
    • Abdominal masses not confirmed and followed by imaging techniques
    • Cystic lesions
    • Lesions situated in a previously irradiated area

• No ocular or mucosal melanoma

• No prior or concurrent liver or brain metastases

• Performance status - ECOG 0-1

• Platelet count at least 100,000/mm^3

• Hemoglobin at least 10 g/dL

• LDH normal

• Bilirubin normal

• AST no greater than 2.5 times upper limit of normal

• Creatinine normal

• No congestive heart failure, angina, or symptomatic cardiac arrhythmia

• No myocardial infarction within the past 6 months

• No severe chronic pulmonary disease

• Not pregnant or nursing

• Fertile patients must use effective contraception

• No primary or secondary immunodeficiency or autoimmune disease

• No currently active second malignancy (e.g., patient has completed therapy and is considered unlikely to have recurrence within 1 year) other than nonmelanoma skin cancer

• At least 4 weeks since prior immunotherapy

• No prior interleukin-2

• No prior whole cell or gp100:209-217(210M)-targeted melanoma vaccine

• No other concurrent cytokines or growth factors

• At least 4 weeks since prior chemotherapy

• At least 1 month since prior systemic corticosteroids

• No concurrent systemic, inhaled, or topical corticosteroids

• At least 1 month since other prior immunosuppressive medication

• No antihypertensive medications from 1 day prior until 2 days after first course

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

50 participants in 1 patient group

Treatment (gp100:209-217, aldesleukin )

Experimental group

Description:

Patients receive gp100:209-217(210M) emulsified in Montanide ISA-51 SC on day 1 and interleukin-2 SC on days 1-5 and 8-13. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. Patients with a CR receive 3 additional courses after achieving CR.

Treatment:

Biological: aldesleukin

Biological: gp100:209-217(210M) peptide vaccine

Other: laboratory biomarker analysis